By Rob Curran
Shares of Tango Therapeutics plunged after it logged a wider third-quarter loss and said it would test a cancer drug in combination with another company's product candidate.
The Boston biotech firm posted a third-quarter loss of $29.2 million, or 27 cents a share, wider than the loss of $22.3 million, or 23 cents a share, in the prior-year period.
Revenue inched up to $11.6 million from $10.7 million.
During the quarter, Tango said its TNG462 cancer-drug candidate showed promise in an early-stage phase 1/2 clinical trial, prompting the company to advance the treatment through a development program. The biotech firm struck a deal with rival Revolution Medicines to test TNG462 in combination with Revolution's RAS$(ON)$ multi- and G12D-selective inhibitors.
Tango said Maeve Waldron-Lynch joins as senior vice president and head of clinical development later in November.
Shares of Tango plunged 35% to $3.38, premarket.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
November 06, 2024 09:14 ET (14:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。